Saxenda vs Zepbound: Weight Loss Injection Comparison

Compare Saxenda and Zepbound using their current labels, separate placebo-controlled weight-loss findings, distinct injection schedules, storage, risks and access.

Overview: Saxenda and Zepbound

Saxenda contains liraglutide for weight management; Victoza is the diabetes product. Both are Novo Nordisk products. Liraglutide’s palmitoyl modification supports a roughly 13-hour half-life and daily subcutaneous use. Semaglutide has different substitutions and a C18 fatty diacid side chain supporting approximately a one-week half-life; both use albumin binding. Half-life and sequence similarity do not independently prove superior receptor affinity or a numerical clinical advantage.

The current Mounjaro label covers glycemic control in type 2 diabetes from age 10 and cardiovascular-event risk reduction in adults with type 2 diabetes at high cardiovascular risk. Zepbound contains tirzepatide but has adult weight-management and moderate-to-severe obstructive-sleep-apnea indications in adults with obesity. Approval of one brand does not automatically transfer its indication to another.

Mechanism of Action: How They Work

Liraglutide and tirzepatide have distinct pharmacology, but no receptor-based numerical efficacy comparison follows.

Saxenda (Liraglutide): Single GLP-1 Agonist

Saxenda contains liraglutide for weight management; Victoza is the diabetes product. Both are Novo Nordisk products. Liraglutide’s palmitoyl modification supports a roughly 13-hour half-life and daily subcutaneous use. Semaglutide has different substitutions and a C18 fatty diacid side chain supporting approximately a one-week half-life; both use albumin binding. Half-life and sequence similarity do not independently prove superior receptor affinity or a numerical clinical advantage.

Zepbound (Tirzepatide): Dual GLP-1/GIP Agonist

Semaglutide activates the GLP-1 receptor; tirzepatide activates GIP and GLP-1 receptors. Both can improve glucose regulation and reduce appetite. Dual receptor activity is a mechanistic distinction, not proof of better outcomes for every person or of preserved muscle. This comparison concerns the named weekly injections unless another formulation is specified.

Weight Loss Efficacy: Clinical Trial Results

Both have positive clinical trials, with different populations, background care and follow-up.

Saxenda Efficacy Data

SCALE Obesity and Prediabetes randomized 3,731 adults without type 2 diabetes to daily liraglutide 3 mg or placebo with lifestyle counseling for 56 weeks. Mean loss was 8.4 versus 2.8 kg using last-observation-carried-forward imputation; 63.2% versus 27.1% lost at least 5%. This Novo Nordisk-funded trial provides positive liraglutide evidence, not a matched tirzepatide or semaglutide comparison.

Zepbound Efficacy Data

STEP 1 tested weekly semaglutide 2.4 mg in 1,961 adults without diabetes: mean treatment-policy loss was 14.9% versus 2.4% with placebo at 68 weeks. SURMOUNT-1 tested tirzepatide in 2,539 adults without diabetes: treatment-regimen losses at 72 weeks were 15.0%, 19.5% and 20.9% at 5/10/15 mg versus 3.1% with placebo. These separate trials do not establish a head-to-head difference; the frequently quoted 22.5% uses a different estimand.

SURMOUNT-1 is placebo-controlled, not a Saxenda head-to-head trial. SURMOUNT-3 used a selected lifestyle run-in; its figures must not be assigned to all new starters or substituted for SURMOUNT-1.

Dosing Schedules and Injection Frequency

Daily and weekly schedules offer different practical routines; one does not guarantee adherence or tolerability.

Saxenda (Liraglutide) Dosing

Saxenda starts at 0.6 mg daily with weekly 0.6-mg steps toward 3 mg; its label includes response-based discontinuation and interruption/restart instructions. Victoza has a separate daily diabetes schedule with a 1.8-mg maximum. These are label summaries, not instructions to substitute brands, escalate every six days or treat maximum doses as necessary for everyone.

Zepbound (Tirzepatide) Dosing

Mounjaro starts at 2.5 mg once weekly; increases in 2.5-mg steps require additional glycemic control and at least four weeks at the current dose. Zepbound starts at 2.5 mg weekly for four weeks, then 5 mg; later increases require at least four weeks at the current dose, considering response and tolerability. Adult maximum is 15 mg; Mounjaro’s pediatric maximum is 10 mg. Zepbound weight-management maintenance doses are 5, 10 or 15 mg, whereas its OSA maintenance doses are 10 or 15 mg. A maximum is not a target for everyone.

Zepbound has multiple presentations with separate refrigerated and room-temperature limits. It is inaccurate to describe all pens as needing no refrigeration or to transfer a Saxenda device routine.

Side Effects and Tolerability

Similar symptom types do not prove identical rates or a daily-nausea accumulation versus weekly-recovery pattern.

Common Side Effects

Nausea, diarrhea, vomiting, constipation and abdominal symptoms occur with both treatments, commonly during escalation. Separate label pools differ in dose, population and follow-up, so a table of unmatched percentages cannot rank tolerability. SURMOUNT-5 reported mainly mild-to-moderate GI events during escalation; it was not designed to establish a definitive safety winner. Symptoms may improve, persist or require dose changes or stopping.

Serious Adverse Events

Both products have boxed rodent thyroid C-cell tumor warnings and formal MTC/MEN2/hypersensitivity contraindications. Pancreatitis, gallbladder disease, severe GI effects, dehydration-related kidney injury and other label precautions matter. A thyroid cancer contraindication is not merely “use with caution.”

Cost and Insurance Coverage

Compare a current itemized quote for the exact product, dose, device and prescription indication. Original estimates of roughly $800–$1,500 monthly for branded injections were historical examples, not current offers. Coverage, deductibles, quantity limits and manufacturer-program eligibility vary; commercial savings cards generally have exclusions and do not guarantee a $25 copay or uninsured access. Medicare/Medicaid decisions depend on the covered indication and applicable rules rather than a blanket exclusion of every use.

Retail Pricing (Without Insurance)

Old retail ranges do not establish identical current price or a valid cost-per-pound ranking.

Insurance Coverage Considerations

Compare the current exact prescription and program terms. A manufacturer list price, pharmacy retail quote, self-pay offer and insured copay are different figures; introductory dose offers are not maintenance prices. Neither a $499 Foundayo example nor a $1,349 Wegovy or $1,086 Zepbound historical list-price example establishes today’s personal cost or an annual saving. The CMS GLP-1 Bridge is a separate, conditional pathway for qualifying beneficiaries and products; it does not mean all Medicare patients receive either medicine for $50. Check plan, indication, formulation and eligibility.

Copay Assistance Programs

Novo Nordisk, not Lilly, manufactures Saxenda. Novo’s Saxenda information describes a strategic discontinuation with last wholesaler shipments expected in late January 2027, not a safety or quality withdrawal. Check actual availability and alternatives without abruptly stopping prescribed care.

Quick Comparison Table

Which Should You Choose?

Choose around the actual treatment goal, approved indication, prior response, risks, available formulations and sustainable access. More average weight loss does not necessarily mean the best option for an individual. Type 2 diabetes, established cardiovascular disease, CKD, obesity or OSA can change which product-specific evidence matters. An arbitrary three-month percentage threshold or cost-first ladder does not settle every decision.

Choose Saxenda If:

Saxenda has positive weight-management evidence and may fit an eligible person’s response, tolerance or coverage; current supply plans also matter.

Choose Zepbound If:

The current Mounjaro label covers glycemic control in type 2 diabetes from age 10 and cardiovascular-event risk reduction in adults with type 2 diabetes at high cardiovascular risk. Zepbound contains tirzepatide but has adult weight-management and moderate-to-severe obstructive-sleep-apnea indications in adults with obesity. Approval of one brand does not automatically transfer its indication to another.

Choose around the actual treatment goal, approved indication, prior response, risks, available formulations and sustainable access. More average weight loss does not necessarily mean the best option for an individual. Type 2 diabetes, established cardiovascular disease, CKD, obesity or OSA can change which product-specific evidence matters. An arbitrary three-month percentage threshold or cost-first ladder does not settle every decision.

The calculator explains arithmetic and does not prescribe a dose or prove most clinicians prefer one first-line medicine.

Related reading: tirzepatide dosage calculator.

Related reading: weight loss peptides guide.